Sustainability & Climate

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Biotech pioneer Stratum Biosciences lands $2M seed funding to scale its AI platform, mining 200,000 skin samples to unlock new frontiers in dermatology.

For decades, ill-fitting gear has endangered female first responders. Now, a new initiative aims to deliver safety, equity, and dignity through design.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

A major investment aims to develop biomarkers for TAND, the neuropsychiatric challenges affecting most with TSC, offering new hope for families.

Amid a major leadership change, Sonorous Neurovascular pushes its pioneering BosSTENT™ for pulsatile tinnitus sufferers closer to market approval.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

Launched in 2025, Mellow hit $110M in sales in nine months by mastering TikTok. Now it aims to own the $300B sleep market, but can the product live up to the hype?

A new report shows 6 in 10 Brits now prefer revisiting holiday spots. Discover the rise of the 'Return Economy' and how it's reshaping travel.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

From a $20k loan to a major wellness player, a women-founded brand proves sustainability and science are the future of sleep and business.

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

As outdoor recreation booms and volunteer support wanes, a tech and auto partnership is scaling up efforts to restore threatened public land trails.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

A promising oral therapy for a rare, aggressive lung cancer is now under review in Europe, offering a new option for patients with limited treatments.

With $12M in new funding, a Houston startup is deploying its NASA-derived HVAC retrofit that promises to slash building energy bills by over 50%.

Teamsters at a critical Lansing food safety firm will rally Friday, alleging unfair labor practices are derailing talks for a fair first contract.

As GLP-1 drug demand soars, Nordic Cold Chain Solutions launches a new lab to solve the complex puzzle of keeping these sensitive medicines safe.